Destiny Pharma PLC Clinical Study Patient Recruitment Update (7030B)
12 October 2020 - 5:00PM
UK Regulatory
TIDMDEST
RNS Number : 7030B
Destiny Pharma PLC
12 October 2020
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Clinical Study Patient Recruitment Update
101 patients recruited in Phase 2b clinical study of lead asset
XF-73 for the prevention of post-surgical infections
Recruitment on track to complete by year-end and report results
in Q1 2021
Brighton, United Kingdom - 12 October 2020 - Destiny Pharma plc
(AIM: DEST), a clinical stage biotechnology company focused on the
development of novel products to prevent life threatening
infections today announces an update on its XF-73 Phase 2b clinical
study with 101 patients out of the target of 125 now recruited.
The Phase 2b clinical study is recruiting patients undergoing
open heart surgery in United States and Europe. Subject to
recruitment being slowed again by the impact of COVID-19, the study
is expected to complete recruitment before the end of the year and
report results in Q1 2021.
Neil Clark, Chief Executive Officer of Destiny Pharma, said :
"We are very pleased to report that we have passed the one hundred
patients mark in our lead clinical study testing XF-73 as a novel
product preventing the incidence of post-surgical infections. This
follows a protocol amendment with the FDA and promising interim
safety data announced earlier in the year. We expect to complete
recruitment before the end of the year and report results in early
2021 as we start preparations for the Phase 3 study."
Details of Phase 2b Study
The ongoing Phase 2b trial is a multi-centre, randomised,
blinded, placebo-controlled study of multiple applications of a
single concentration of XF-73 nasal gel to assess the
microbiological effect of XF-73 on commensal Staphylococcus aureus
nasal carriage in 125 patients scheduled for open heart
surgery.
The Phase 2b study design is closely related to the successful
2016 clinical trial, which was funded by the National Institute of
Allergy and Infectious Disease (part of the US National Institute
of Health) and demonstrated the clinical efficacy of XF-73 versus
placebo in reducing nasal Staphylococcus aureus carriage in healthy
volunteers.
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0) 1273 704 440
pressoffice@destinypharma.com
Optimum Strategic Communications
Mary Clark, Shabnam Bashir, Manel Mateus
+44 (0) 203 174 1789
destinypharma@optimumcomms.com
finnCap Ltd (Nominated Advisor Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0) 20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330
About Destiny Pharma
Destiny Pharma is an established, clinical stage, innovative
biotechnology company focused on the development and
commercialisation of novel medicines that can prevent
life-threatening infections. The company's lead programme is
undergoing a Phase 2b clinical trial and is targeting the
prevention of post-surgical hospital infections including MRSA. The
XF drug candidates are being developed for the prevention and
treatment of life-threatening infections caused by
antibiotic--resistant bacteria, often referred to as "superbugs".
Tackling anti-microbial resistance has become a global imperative
recognised by the World Health Organization (WHO) and the United
Nations, as well as the G7 and the G20 countries. Destiny Pharma is
also collaborating with SporeGen(R) to co-develop a novel,
preventative product for COVID-19. For further information, please
visit https://www.destinypharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
STREAXENEAEEFFA
(END) Dow Jones Newswires
October 12, 2020 02:00 ET (06:00 GMT)
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From Apr 2024 to May 2024
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From May 2023 to May 2024